Prograf (tacrolimus) moderately improves myasthenia gravis (MG) in patients with inadequate response to glucocorticoids (GCs), a new study from China shows. The study, “Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China,” appeared in the…
News
ARGX-113, an investigational therapy for myasthenia gravis (MG), is progressing in a Phase 2 clinical trial (NCT02965573) that is still enrolling patients, according to the biotech company argenx in its quarterly update. MG is an autoimmune disorder, mostly characterized by abnormal responses of the patients’ own T-cells (a type…
Accordant’s myasthenia gravis services program has been accredited by an organization that assesses whether providers meet standards for caring for people with rare diseases. The accreditation came from the National Committee for Quality Assurance, which also certified that Accordant met standards for caring for patients with several other rare diseases. The…
The European Commission (EC) has approved Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The approval of Soliris, marketed by Alexion Pharmaceuticals, follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the…
Muscle regeneration in myasthenia gravis likely is delayed as a result of the impaired functioning of muscle stem cells, called satellite cells (SCs), a study has found. The study, “Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration,” was published in the journal Acta Neuropathologica.
Researchers have found a correlation between all types of thyroid disorders and myasthenia gravis, particularly in women and older men, a study reports. The research, “The Concomitant Association of Thyroid Disorders and Myasthenia Gravis,” was published in the journal Translational Neuroscience. Surprisingly, the first study suggesting an association…
Heavier myasthenia gravis patients are at higher risk of having respiratory failure or other complications after their thymus is removed, a study reports. Doctors should monitor such patients closely to prevent severe postoperative complications, researchers contended. The thymus is a gland in the chest that plays a role in the immune…
Removing the thymus is an effective way to treat people with ocular myasthenia gravis, according to an analysis of previously published data that could resolve the controversy around the treatment. The Chinese researchers’ conclusion applied to thymectomies — or surgical removal — of thymuses that do not contain tumors. Myasthenia gravis is eliminated…
News
Thymus Surgery Plus Medicine Beats Medicine Alone as a Myasthenia Gravis Treatment, Trial Reports
Medical professionals have debated whether removing the thymus of a person with myasthenia gravis is an effective way of treating their disease. A Phase 3 clinical trial seems to have settled the debate. It concludes that the surgery, known as a thymectomy, plus medication is better than medication alone in…
ALS and myasthenia gravis have features in common, including an underlying immunological mechanism and alterations in communication junctions between muscle and nerve cells, Chinese researchers report. The Peking Union Medical College team published its study in Frontiers in Neurology. Its title was “Amyotrophic Lateral Sclerosis and Myasthenia Gravis Overlap Syndrome: A…
Recent Posts
- New MG app helps doctors track symptoms between clinic visits
- How to make room for intimacy when chronic illness enters a relationship
- I do not want to lose myself to myasthenia gravis
- Robotic thymectomy is safe, effective for MG patients even after age 65
- My cousins’ love and loyalty remind me to choose connection, not division